Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

HPB

Volumn 17, Issue 10, 2015, Pages 942-952

  Aldakkak, Mohammed ^a   Christians, Kathleen K ^a   Krepline, Ashley N ^a   George, Ben ^a   Ritch, Paul S ^a   Erickson, Beth A ^a   Johnston, Fabian M ^a   Evans, Douglas B ^a   Tsai, Susan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; GEMCITABINE; CARBOHYDRATE ANTIGEN 199, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE COMPLICATION; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; ADENOCARCINOMA; BIOPSY; BLOOD; FOLLOW UP; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS, TUMOR; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84941878704     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12448     Document Type: Conference Paper

References (38)

1. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al., (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10: 1199-1210; discussion 210-1.
2. Winter JM, Brennan MF, Tang LH, D'Angelica MI, Dematteo RP, Fong Y, et al., (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 19: 169-175.
3. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA,. (2014) Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst 106: dju011.
4. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al., (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27: 1806-1813.
5. Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH, et al., (2012) Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg 147: 753-760.
6. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS,. (2007) National failure to operate on early stage pancreatic cancer. Ann Surg 246: 173-180.
7. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL,. (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24: 2897-2902.
8. Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, et al., (2009) Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 16: 3316-3322.
9. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, et al., (2009) Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 13: 2050-2058.
10. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D,. (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93: 740-743.
11. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al., (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9: 132-138.
12. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al., (2013) CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20: 2188-2196.
13. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, et al., (2014) Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 21: 4351-4358.
14. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al., (2010) Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17: 1794-1801.
15. Appel BL, Tolat P, Evans DB, Tsai S,. (2012) Current staging systems for pancreatic cancer. Cancer J 18: 539-549.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
17. Christians KK, Tsai S, Tolat PP, Evans DB,. (2013) Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. J Surg Oncol 107: 33-38.
18. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. (2010) Exocrine and Endocrine Panceas. In: AJCC Cancer Staging Manual, 7th edn. New York: Springer, pp. 241-250. ISBN: 978-0-387-88440-0.
19. Clavien PA, Sanabria JR, Strasberg SM,. (1992) Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 111: 518-526.
20. Tran Cao HS, Balachandran A, Wang H, Nogueras-Gonzalez GM, Bailey CE, Lee JE, et al., (2014) Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg 18: 269-278; discussion 78.
21. Raman SP, Kawamoto S, Law JK, Blackford A, Lennon AM, Wolfgang CL, et al., (2013) Institutional experience with solid pseudopapillary neoplasms: focus on computed tomography, magnetic resonance imaging, conventional ultrasound, endoscopic ultrasound, and predictors of aggressive histology. J Comput Assist Tomogr 37: 824-833.
22. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al., (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.
23. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al., (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3487-3495.
24. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, et al., (2010) Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8: 972-1017.
25. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD,. (2009) Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16: 1736-1744.
26. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al., (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 23: 1713-1722.
27. Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, et al., (2009) Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg 13: 1791-1797.
28. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, et al., (2009) Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115: 2630-2639.
29. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA,. (2008) Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37: 269-274.
30. Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al., (2012) Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 214: 33-45.
31. Sietses C, Beelen RH, Meijer S, Cuesta MA,. (1999) Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Langenbecks Arch Surg 384: 250-258.
32. Shakhar G, Ben-Eliyahu S,. (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10: 972-992.
33. Detry O, Honore P, Meurisse M, Jacquet N,. (2000) Cancer in transplant recipients. Transpl Proc 32: 127.
34. Penn I,. (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55: 742-747.
35. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, et al., (1999) Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 45: 54-61.
36. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM,. (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47: 5501-5503.
37. Mann DV, Edwards R, Ho S, Lau WY, Glazer G,. (2000) Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26: 474-479.
38. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, et al., (2008) Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 53: 3213-3217.